13 December 2022
Shield Therapeutics and Viatris sign Collaborative Sales Agreement for Accrufer® in the United States
Shield Therapeutics plc today announced that it has entered into an exclusive, multi-year agreement with Viatris Inc. (NASDAQ: VTRS), a global healthcare company, to cocommercialize Accrufer®
The oral iron market in the United States is an estimated US$2 billion market opportunity, and Accrufer® is the only FDA approved oral iron to treat iron deficiency, with or without anemia. This new collaboration expands the commercial footprint and resources for Accrufer®, as the brand aspires to be the oral iron of choice in the US market. The collaboration will result in a 100 person sales team who will promote Accrufer® to over 12,000 Health Care Professionals who write the majority of oral iron prescriptions. In addition, Shield and Viatris will also deploy additional resources in digital marketing, market access, distribution and commercial operations via a shared cost model.
Greg Madison, Shield CEO, commented: “We are thrilled to work with Viatris via the company’s unique Global Healthcare Gateway®, in bringing Accrufer® to patients suffering from iron deficiency, with or without anemia. Shield has built a solid foundation for Accrufer® since our launch with a small commercial sales team and we believe this agreement with Viatris will markedly accelerate the adoption and growth of Accrufer®. Viatris’ well established commercial infrastructure including strong prescriber relationships, best in class digital marketing and direct to patient capabilities, and extensive market access experience makes them an ideal partner for Shield and Accrufer®. Working together with Viatris, I believe Accrufer® can become the oral iron treatment of choice and we look forward to getting started right away.”
Jose Cotarelo, Head of North America, Viatris, commented: “We are excited that through our Global Healthcare Gateway® we have become the Partner of Choice® for Shield to support the commercialization of Accrufer® in the U.S. and thus expand access to those living with iron deficiency. This collaboration is a great opportunity to leverage our commercial capabilities while furthering Viatris’ mission to empower people worldwide to live healthier at every stage of life.”
For further details click here